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SnmmJary 
We have previously  reported that lipopolysaccharide  (LPS) binding protein (LBP) opsonizes 
endotoxin (LPS) for recognition by CD14 on phagocytes.  Here we show that normal human 
plasma contains high titers of an activity that also binds LPS (Re, 595) and mediates recognition 
by CD14. Opsonization of LPS-coated particles with plasma enables the particles to be bound 
by  phagocytes.  Further,  opsonization  with  plasma  also enables  subnanogram-per-milliliter 
concentrations of LPS to induce dramatic alterations  in the function of leukocyte integrins on 
polymorphonudear leukocytes and to induce secretion of tumor necrosis factor by monocytes, 
suggesting that opsonization by factors in plasma may be important in responses of cells to endotoxin. 
The opsonic activity in plasma appears distinct from LBP since it is not blocked by neutralizing 
antibodies  against LBP. Surprisingly,  the opsonic activity of plasma is not present in a single 
protein species, but at least two species must be combined to observe activity. Further, the opsonic 
activity of plasma for LPS is blocked by addition of protease inhibitors, suggesting that proteolytic 
activity or activities are required for opsonization. These properties are suggestive of the action 
of a protease cascade, but opsonic activity of plasma is not affected by blockade or depletion 
of either the complement or dotting cascades. We propose the name "septin" to describe this 
novel LPS-opsonizing  activity in plasma. 
ukocytes recognize bacterial  LPS (endotoxin) through 
several mechanisms (1). CD18 antigens (2) and the scav- 
enger receptors  (3) on leukocytes have been shown to bind 
particulate and dispersed LPS, respectively. This binding may 
result in uptake and degradation of LPS but is not associated 
with stimulation of the ceUs (3, 4).  We have recently de- 
scribed a different means of recognizing LPS in which a soluble 
protein, rather than a membrane-bound molecule, performs 
the initial binding to LPS. LPS binding protein (LBP)  1 binds 
to both dispersions of LPS (5) and to LPS on the surface of 
particles  (6). The resulting LPS/LBP complexes are recog- 
nized by the receptor CD14 on PMN (7), monocytes, and 
macrophages (MO) (8). "Opsonization" of bacteria with LBP 
enables phagocytes to bind and phagncytose the particles (6) 
in a CD14-dependent fashion  (S. D. Wright, unpublished 
observations),  thus resulting in clearance of LPS. 
CD14 may also initiate the dramatic responses of leuko- 
cytes to picogram-per-milliter concentrations of endotoxin. 
1 Abbreviations used in this  ~Fer: DFP, diisopropylphosphofluoridate;  LBP, 
LPS binding protein; MO, macrophage; NHP, normal human plasma. 
PMN show the most rapid responses with priming for en- 
hanced oxidative activity (9) and enhanced activity of leuko- 
cyte integrins (7) observed after 15-30 min of exposure to 
LPS. Both of these responses of PMN require LBP (7, 10) 
or serum (7, 11), and both can be blocked by anti-CD14 mAbs 
(7, and M. J. Pabst, personal communication). Monocytes 
and MO respond to LPS by synthesizing cytokines such as 
TNF, Ibl, and IL-6 within 1-2 h. TNF production by rabbit 
MO in response to sub nanogram-per-milliliter doses of LPS 
requires LBP (12), and blockade of CD14 on human mono- 
cytes prevents TNF production (8). These data suggest that 
CD14 is the principal  mediator of responses to picogram- 
per-milliter concentrations of LPS, and that LBP or other 
serum proteins are needed for recognition of LPS by CD14. 
Here we have examined the proteins in serum or plasma 
that opsonize LPS-coated particles and mediate binding to 
CD14. We find that plasma from healthy human volunteers 
contains an enormous amount of this opsonic activity. The 
activity is not contained in a single protein fraction, but at 
least two species must be combined to duplicate the activity 
in plasma. Moreover, opsonic activity of plasma is completely 
inhibited by inhibitors of proteolysis. We suggest that LPS 
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propose the name "septin"  to define this  activity. 
Materials  and Methods 
Reagents.  Fresh frozen normal human plasma (NHP) from blood 
drawn into acid citrate dextrose and human fibronectin was sup- 
plied by the New York Blood Center. Human plasmas deficient 
in Hageman Factor, preka[iikrein, factor IX, high molecular weight 
kininogen, and complement protein C5 were from Sigma Chem- 
ical Co. (St. Louis, MO); plasma deficient in protein C was from 
American Diagnostica (Greenwich, CT); and serum deficient in 
complement proteins C1, C2, and factor B were from Quidel (La 
Jolla, CA). Pefabloc SC (p-aminoethylbenzenesulfonyl  fluoride) was 
from Centerchem Inc. (Stamford, CT); diisopropylphosphofluori- 
date (DFP), PMSF, aprotinin, soybean trypsin inhibitor (SBTI), 
and benzamidine were from Sigma Chemical Co.; and Chymostatin 
was from Calbiochem-Behring Corp. (LaJolla, CA). LPS (Re, 595) 
was  from List Biologicals  (Campbell, CA). 
Goat anti-rabbit LBP and preimmune serum was  a generous 
gift of Dr. R. Ulevitch (Scripps Institute, La JoUa, CA). IgG from 
this serum was purified by protein G chromatography, mAb 3C10 
(13) against  CD14 was also purified from ascites fluid by protein 
G chromatography. 
Human  LBP  was  purified  from  human  ascitic  fluid  by  a 
modification of the method of Tobias et al. (5). Ascitic fluid was 
first brought to 1 mM PMSF,  1 mM Pefabloc SC, 0.05% DFP, 
and 5 mM EDTA, and passed over BioRex 70 equilibrated in 50 
mM phosphate, pH 7.3, 40 mM NaC1, and 2 mM EDTA. Proteins 
were eluted with a linear gradient of NaC1, and fractions were col- 
lected into the tubes containing Pefabloc SC and aprotinin. Frac- 
tions containing LBP were pooled and further purified by chroma- 
tography on a Mono Q  column as described below.  The LBP 
obtained by this procedure appeared as a single band on SDS gels 
of "064,000 Mr, and NH2-terminal sequencing showed identity 
with the deduced sequence of human LBP (12). 
Cells.  Monocyte-derived MO  were  obtained  by  culturing 
purified human monocytes in Teflon beakers for 3-10 d as described 
(14). On the day of the experiment, MO were suspended in Dul- 
becco's PBS containing 0.5 mg/ml human serum albumin (Armour 
Pharmaceuticals,  Kankakee,  IL), 0.3 U/ml aprotinin, and 3 mM 
glucose (HAP buffer), and monolayers were obtained by incubating 
2,500 MO in Terasaki we[Is for 45 min at 37~  PMN were purified 
from fresh blood by the method of English and Anderson (15) and 
were suspended in HAP buffer. Monolayers were obtained by adding 
10,000 PMN to Terasaki wells and incubating for 20 min at 37~ 
Production of TNF by monocytes was measured using freshly 
prepared PBMC. Preliminary studies showed that preparations of 
mononuclear cells containing platelets  mounted a substantial  re- 
sponse to LPS even in the absence of serum, suggesting that phtelets 
may substitute for serum in this assay. We therefore used platelet- 
free  preparations  of  fresh  mononuclear  cells  obtained  by  a 
modification of the method of Pawlowski  et al. (16). Blood was 
drawn into an equal volume of saline containing 5 mM EDTA and 
20 U/ml heparin. After centrifugation on a Ficoll-Hypaque gra- 
dient, the overlying plasma  and the mononuclear ce[i layers were 
separately recovered. After two low-speed washes, the mononuclear 
cells were suspended  in the recovered autologous plasma  and in- 
cubated for 10 min at 37~  This step dutes bound platelets from 
the monocyte surface. Cells were then washed into RPMI  1640 
containing  10  /zg/ml  human  c~2-macroglobalin  (Calbiochem- 
Behring Corp.), and 20,000 calls were added to each Terasaki well. 
The human kidney cell line 293-S was stably transfected with 
a full-length gene encoding CD14 (M. P and G. E. Mark, unpub- 
lished studies).  These cells grow as a monolayer and are passaged 
by suspending in EDTA. The untransfected cells express no CD14 
by FACS  |  analysis, but the transfectants express CD14 at levels 
comparable to those on monocytes. Monolayers were obtained by 
suspending  the  cells  in  HAP  buffer  and  incubating  5,000  in 
fibronectin-coated Terasaki we[is (17) for 60 min at 37~ 
Sheep erythrocytes (E) were coated with C3bi or LPS to yield 
EC3bi or ELPS by methods previously described (2, 6). The dose 
of LPS used to prepare the ELPS was  1 #g/4  x  107 E. EC3bi 
were suspended  in 2.5 #M veronal buffer, pH 7.5, 75 raM NaC1, 
2.5% dextrose, 0.05% gelatin, 0.15 mM CaCI2, 0.5 mM MgC12 
(DGVB2+), and ELPS were suspended in 5 mM veronal buffer, pH 
7.5, 150 mM NaC1, 0.1% gelatin, 1 mM EDTA (EDTA-GVB2-). 
Opsonization of ELPS.  Opsonization of ELPS by plasma was 
measured by one of two procedures. In the first,  monolayers of 
MO were washed into PBS containing 1 mM EDTA, then dilu- 
tions of plasma  and 5  x  10  s ELPS were added.  Wells were in- 
cubated for 15 rain at 0~  to allow opsonization and settling of 
the E, then for 15 rain at 21~  to allow binding to the MO. The 
cultures were next inverted for 20 rain to allow gravity to gently 
remove nonadherent erythrocytes from the MO, and attachment 
orE was scored by phase contrast microscopy. EDTA was included 
throughout the assay to prevent clotting or deposition of comple- 
ment, but similar malts were obtained with serum diluted in buffers 
containing calcium and magnesium (Dalbecco's PBS). 
In a second form of this assay, ELPS were opsonized by incuba- 
tion with dilutions of  plasma, washed, and then added to monohyers 
of MO. After 30 min at 21~  cultures were inverted and washed 
as above. This "two-step" assay yielded titers 3-10-fold greater than 
the single-step  assay above. For both forms of the assay, the data 
are presented as attachment index, the number of E bound per 100 
MO. The opsonization detected by these assays is termed "septin 
activity;' and the septin titer is the dilution of plasma needed for 
half-maximal rosetting. All experiments using these assays were 
repeated at least  three times with NHP from different donors. 
Chromatograph,/.  Bio-Rex 70 resin was equilibrated with 50 mM 
phosphate, pH 7.3, 40 mM NaC1, and 2 mM EDTA, then incubated 
batchwise for 18 h with a sixfold volume excess of neat human 
plasma containing 2 mM EDTA. The resin was then washed, poured 
into a column, and eluted with 50 mM phosphate, pH 7.3, 0.5 
M  NaC1.  The eluate contained •0.25%  of the protein in  the 
starting material. Septin assays showed that opsonic activity was 
quantitatively adsorbed from the plasma by exposure to Bio-Rex, 
and that 50-70% of the activity was recovered in the eluate. The 
eluate from the Bio-Rex column was dialyzed against 20 raM "Iris, 
pH 8.5, applied to a Mono Q column and eluted with a gradient 
of NaC1 (see Fig.  4). 
Activation of CR3 on PMN.  The activation of the leukocyte 
integrin, CR3, was measured by determining the ability of PMN 
to bind EC3bi using one of two procedures. In the first, monolayers 
of PMN were washed into PBS containing 1 raM EDTA, and dilu- 
tions of LPS and plasma were added.  EDTA was included in this 
step to insure that complement would not be activated by the LPS. 
After a 15-min incubation at 37~  the monolayers of PMN were 
washed with PBS containing divalent cations,  5  x  10  s EC3bi 
were added, and cultures were incubated for 30 min at 37~  Nonad- 
herent EC3bi were removed by vigorous washing, and the attach- 
ment index was  measured (7). 
In a second form of this assay, PMN were activated by adher- 
ence to LPS-coated, opsonized culture wells. Terasaki wells were 
incubated for 2 h with 100 ng/ml LPS, washed thoroughly, then 
air dried. The surface were then opsonized by incubation with di- 
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PMN were added to the wells and incubated for 15 min at 37~ 
Activation of  CR3 was measured by adding EC3bi and continuing 
the incubation  for 20 rain at 37~ 
TNF Secretion by Monocytes.  Production of TNF-c* by freshly 
isolated monocytes in response to LPS was measured by one of two 
procedures. In the first, dilutions of LPS and NHS were added to 
mononuclear cells and incubated for 5 h at 37~  TNF in the su- 
pernatant  fluid was measured by ELISA in Terasaki plates as de- 
scribed (18). This assay  employed  an alkaline phosphatase-conjugated 
second antibody and was read on a fluorescence  scanner (Cytofluor 
2300; Millipore, Bedford, MA) using the fluorogenic substrate At- 
tophos (JBL Scientific, San Luis Obispo, CA).  In a second form 
of the assay, TNF production was induced upon interaction of  mono- 
cytes with LPS-coated, opsonized culture wells as described above 
for PMN, with the exception that 20 ng/ml LPS was used for 
coating  the substrates. 
Results 
Plasma Constituents Mediate Binding of LPS-coated Particles 
to MO.  Addition of human plasma to mixtures of ELPS 
and MO caused the ELPS to attach firmly to MO. All plasma 
samples tested (>30) caused comparable binding, with the 
attachment index rising from 16.4  +_  9.6 for ELPS alone to 
496  _+  192 in the presence of 0.5% plasma (n  =  10). The 
binding of ELPS to MO observed in these studies is unlikely 
to be due to complement deposition on the ELPS or interac- 
tions of LPS with CD18 molecules, since the studies were 
performed in the presence of 1 mM EDTA (see Materials and 
Methods), conditions that block complement activity and 
the function of CD18 molecules (2,  14). The MO in these 
studies were taken from serum-containing cultures, indicating 
that pretreatment of the MO with serum does not enable 
recognition of ELPS. Rather, plasma mediates binding of LPS 
to MO by first interacting with the ELPS to form a stable 
complex. Incubation of ELPS with dilutions of plasma op- 
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Figure 2.  CD14  mediates binding of plasma-opsonized ELPS to MO. 
Monolayers  of  MO, 293-S  ceils, or 293-S  cells  stably  transfected  with CD14 
were established in a 60-rain incubation at 37~  Where indicated, 10 
/~g/ml of the anti-CD14 mAb 3C10 was added to the cells for 10 min 
at 5~  Freshly  washed ELPS or ELPS opsonized  with NHP (0.5%, 15 
rain, 21~  were  then added to the monolayers,  and attachment  was scored 
after a 30-min incubation  at 21~  Additional  studies showed  that incuba- 
tion of  MO with antibodies  against CD16, CD18, and HLA had no effect 
on binding of opsonized ELPS (not shown). 
sonized the erythrocytes such that they bound strongly to 
MO in a subsequent incubation (Fig.  1). Plasma contains a 
great deal of opsonic activity for ELPS, with half-maximal 
binding observed in the two-step opsonic assay using plasma 
diluted '~4,000-fold (Fig.  1). 
ELPS Opsonized with Plasma Bind to CDI4 on MO  Bind- 
ing of plasma-treated ELPS to MO is completely blocked by 
the addition of anti-CD14 mAb (Fig. 2), suggesting that CD14 
is the receptor involved in recognition. The role of CD14 
in binding opsonized ELPS was confirmed using transfec- 
tion studies.  Opsonized ELPS did not bind to untransfected 
293-S cells, but bound avidly to 293-S cells stably transfected 
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Plasma opsonizes ELPS for recognition  by MO. Uncoated 
sheep E (0.5 x  10S/ml; Q) or LPS-coated  E (ELPS; O) were incubated 
with dilutions  of  NHP for 15 min at 21~  in PBS containing 1 raM FJ3TA. 
The E were  washed twice and added to monolayers  of human MO. After 
o  30 rain at 21 C, the monolayers  were  washed, and the attachment  of  ELPS 
to MO was measured  by microscopy.  Resuhs are presented  as attachment 
index, the number  of  erythrocytes  bound per 100 MO, and are representa- 
tive of three separate experiments. 
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Figm'e 3.  Anti-LBP  does  not block  the opsonization  of  ELPS  by plasma. 
Anti-LBP  IgG or preimmune  IgG (50/zg/ml  final  concentration)  was added 
to dilutions  of  NHP or LBP, and these  mixtures  were  added  to monolayers 
of MO. ELPS  were then added, and binding of ELPS to MO was mea- 
sured as described  in Materials and Methods. This study is representative 
of four separate e~periments. 
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Figure 4.  Septin activity is observed only in pools of fractionated pro- 
tein. NHP was fractionated first on BioRex 70 resin and then applied to 
a Mono Q column and ehted with a gradient of NaC1. None of the in- 
dividual 1-ml fractions had detectable septin activity. Aliquots of the frac- 
tions were pooled as shown and diluted to match the starting material. 
Essentially complete recovery of septin activity was observed in the pools 
labeled A and E, but activity in the other pools was undetectable. Septin 
titers (the dilution needed for half-maximal rosetting in the septin assay) 
were determined by graphic analysis of a threefold dilution series begin- 
ning at 1:30. Results were as follows: sample loaded on column, 250; frac- 
tion A, 230; fraction ]3, <30; fraction C, <30; fraction D, <30; fraction 
E, 250; fraction F, <30; fraction G, <30. Triplicate data points in the assay 
varied by <10%. Similar resuks were obtained in three separate experi- 
ments. Solid line, OD2so; dashed line, NaC1 concentration (M). 
with the gene for CD14 (Fig. 2). Moreover,  all binding to 
this transfectant could be blocked with anti-CD14 antibody. 
Thus, ELPS opsonized with plasma bind to CD14 on mac- 
rophages, as do ELPS opsonized with purified LBP (8). 
The OFsonic Activity of Plasraa Appears Distinct from LBR 
LBP is an acute phase reactant reported to be present at low 
levels (~150 ng/ml) in the serum of healthy rabbits (19). To 
determine if LBP accounts for the large amount of opsonic 
activity in plasma of healthy volunteers, binding of ELPS was 
measured in the presence of anti-LBP antibody. While this 
antibody strongly blocked opsonization of ELPS by purified 
LBP, it had no effect on opsonization mediated by plasma 
(Fig. 3). This observation suggests that plasma contains an 
activity distinct from LBP that bridges LPS to CD14 on MO. 
We wiU refer to this opsonic activity as "septin:' 
Septin Activity Requires More than One Protein.  Batch ad- 
sorption of plasma with Bio-Rex 70 resin (see Materials and 
Methods) quantitatively removed septin activity.  The resin 
was poured into a column, washed, and eluted with a step 
gradient of NaC1. Septin activity was recovered in the eluate 
along with 0.25 % of the applied protein. This fractionation 
step is  similar to  that  described by Tobias et  al.  (5)  for 
purification of rabbit LBP, and we have found that LBP in 
human ascites fluid is also enriched by this procedure. The 
partially purified septin was further fractionated on a Mono 
Q  column (Fig. 4). To our surprise, none of the individual 
fractions eluted from this column contained significant septin 
activity.  Pooling of all fractions,  however, resulted in quan- 
titative recovery of septin activity. Additional pooling studies 
indicated that the region of the gradient from 0.14 to 0.30 
M NaC1 (pool E) contained the septin activity,  and this ac- 
tivity was not enhanced by addition of proteins pooled from 
other regions of the gradient. Exclusion of fractions at either 
margin of the active pool resulted in strongly decreased ac- 
tivity (not shown). These experiments indicate that septin 
activity is not produced by a single protein but that at least 
two distinct proteins must be simultaneously present to op- 
sonize ELPS. LBP is unlikely to be among the proteins re- 
quired for septin activity since LBP eluted in pool D  (not 
shown). 
Opsonization with Septin Requires Proteolytic Activity.  Op- 
sonization of ELPS was blocked by the addition of several 
well-characterized  inhibitors of proteolysis to plasma (Table 
1). Detailed studies on inhibition of septin activity were per- 
formed with Pefabloc SC, a water-soluble, covalent inhibitor 
of serine esterases. Inhibition of opsonization was virtually 
complete with 15 mM Pefabloc SC (Fig. 5), and complete 
inhibition of septin activity could be observed over a range 
of concentrations of plasma (Fig.  6).  Importantly, neither 
Pefabloc SC (Fig. 6) nor any of the other inhibitors of pro- 
Table  1.  Protease Inhibitors Block  Opsonization  of ELPS 
by NHP 
Inhibitor  IC~* 
Pefabloc SC  2.5  _+  1.6 mM 
DFP  0.65 mM 
PMSF  0.21-0.40 mM 
Chymostatin  0.05-0.08  mM 
Aprotinin  43  _+  10 #g/ml 
SBTI  33  _+ 17/~g/rnl 
Benzamidine  >10 mM 
LPS  15  _+ 8 ng/ml 
* NHP was diluted to 0.1% in various concentrations  of protease inhi- 
bitors and was then incubated for 15 min at 20~  with ELPS. The ELPS 
were washed, and their ability to adhere to macrophage monolayers was 
assessed. The concentration of inhibitor needed to block opsonization 
by a factor of two was determined by analysis of the resulting inhibition 
curves. Results are the range of two or the average •  SD of three ex- 
periments. None of the protease inhibitors blocked opsonization of ELPS 
by 0.03  /~g/ml LBP in paralld experiments,  suggesting  that they did 
not contain high levels of LPS. Parallel studies indicated that LPS blocked 
opsonization  of ELPS by LBP with an ICs0 of 16  _+  10 ng/ml. 
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Figure 5.  Pefabloc  SC inhibits opsonization of ELPS by plasma. ELPS 
were incubated with 0.1% NHP for 10 rain at 21~  in the presence of 
the indicated concentrations of Pefabloc SC. The treated erythrocytes were 
then washed thoroughly and incubated for 30 min with MO and attach- 
ment measured. 
teolysis (Table 1) inhibited the opsonic activity of LBP. This 
finding indicates  that the inhibition observed is not the re- 
sult of endotoxin contamination of the inhibitors employed, 
and further indicates that the mechanism of action of septin 
is distinct from that  of LBP. 
The site of action of the protease inhibitors is in the plasma 
since pretreatment  of MO or opsonized erythrocytes  with 
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Figure 6.  Pefabloc  SC inhibits opsonization of ELPS by plasma but not 
by LBP. ELPS were incubated with the indicated concentrations of LBP 
or NHP in the presence or absence of 15 mM Pefabloc SC. After a wash, 
binding of cells to MO was measured. 
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Figure 7.  Pefabioc  SC blocks deposition of septin onto ELPS. ELPS 
incubated with 0.5% NHP showed strong binding to MO, and addition 
of 15 mM Pefabloc during this opsonization step blocked opsonization. 
Pefabloc had no effect on binding if added to MO, to ELPS pretreated 
with plasma (15 min, 15 mM, 21~  or during the incubation of op- 
sonized ELPS with MO. 
Pefabloc SC caused no diminution of binding, but addition 
of inhibitor during opsonization with plasma strongly blocked 
the ability to bind MO (Fig. 7). Since opsonization was blocked 
by the classical serine esterase MO inhibitor DFP, and since 
opsonization occurs at neutral pH in the presence of EDTA, 
we suggest that a serine esterase is required for the action 
of septin, and we propose  that the proteins that need to be 
combined to achieve septin activity represent protease and 
substrate. 
Plasma contains an abundance of inhibitors that quickly 
inactivate proteolytic enzymes. Most proteases that act in this 
milieu are derived from inactive zymogens that are not sensi- 
tive to active-site protease inhibitors.  To determine if septin 
enzymes in plasma are similarly insensitive,  10 mM Pefabloc 
SC was incubated with NHP for 15 min at 20~  then re- 
moved by dialysis. A septin assay with 0.1% plasma treated 
in this way showed an attachment  index of 657  _+  50 vs. 
582  _+  18 for untreated,  dialyzed  plasma.  Thus, septin en- 
zymes in resting plasma are insensitive to the protease inhib- 
itor, Pefabolic SC, and the active sites of the enzyme(s) neces- 
sary for septin activity are only made sensitive  to Pefabloc 
SC upon interaction  with LPS. 
Septin Activity Does Not Require the Action of the Comple- 
ment or Clotting Cascades.  The complement cascade is known 
to opsonize particles through the action of several proteo- 
lytic enzymes, and a similar cascade of proteolytic events con- 
trols blood clotting.  Several results,  however,  indicate  that 
neither clotting nor complement cascades are involved in septin 
activity. Both the complement cascade and the clotting cas- 
cade are completely inhibited by removal of divalent cations, 
yet septin activity is measured in chdated buffers. Consump- 
tion of complement activity in serum using either classical 
pathway activators (IgG-coated particles) or alternative pathway 
activators (zymosan particles),  or consumption of clotting 
factors by dotting of blood, bad no effect on septin titers. 
Finally, normal septin titers were observed in sera deficient 
in several complement and dotting proteins (Table 2). These 
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Septin activity is not depleted* by procedures that remove: 
Complement  activity from serum  Clotting activity from plasma 
EDTA (1 mM) 
Classical pathway depletion (EIgG)* 
Alternative pathway depletion (zymosan)* 
Depletion of C1, C2,  C5, factor B 
EDTA (1 mM) 
Clotting and conversion to serum 
Depletion of factor XII (Hageman factor) 
Depletion of factor IX 
Depletion of factor VII 
Depletion of prekallikrein 
Depletion of high molecular weight kininogen 
Depletion of protein C 
* All procedures caused less than a 50% loss in septin titre. Heating serum to 56~  for 60 min caused a 60% loss in septin titer. 
t Classical pathway  and alternative  pathway  activity  were depleted by incubating neat serum with 2 x  109 EIgG or zymosan  particles for 30 min 
at 37~ 
findings indicate that septin activity does not require an in- 
tact complement or clotting cascade. These findings do not, 
however, rule out the participation of  individual enzymes from 
these cascades, such as the complement factors D and C1 in- 
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Figure 8.  Plasma  enables PMN to respond to very low concentrations 
of LPS. A monolayer  of PMN was established in a 20-min incubation  at 
37~  (A) The cells were then incubated  for 15 rain at 37~  with NHP 
(0.25%) or LBP (0.5 #g/ml), and dilutions  of  LPS in an EDTA-containing 
buffer. Cells were washed and the activity  of CR3 was determined. (B) 
Monolayers of PMN were incubated in an EDTA-containing  buffer for 
15 min at 37~  in the presence  or absence  of  0.5 ng/ml LPS and dilutions 
of NHP, and CR3 activity  determined as above. 
hibitor, or the dotting enzymes factors II, V, X, XI, plasmin, 
or plasminogen activator. 
Septin Mediates Stimulation of  PMN by LPS.  We have pre- 
viously shown that PMN respond to LPS/LBP complexes 
by upregulating the adhesive capacity of CR3 (7), the receptor 
for complement protein C3bi. To determine if septin is also 
capable of mediating stimulation of PMN by LPS, PMN were 
incubated with dilutions of LPS in the presence  of LBP or 
NHP (Fig. 8 A). Concentrations of LPS alone as high as 10 
ng/ml caused no activation of CR3. Addition of LBP en- 
abled a half-maximal response to ",0.2 ng/ml LPS, confirming 
our previous findings (7).  NHP enabled a strong response 
to even lower concentrations of LPS, with '~0.01 ng/ml being 
sufficient  for a half-maximal response.  The ability of NHP 
to enable this response to LPS was concentration dependent, 
with half-maximal activity observed at dilutions of'v 1/3,000 
(Fig. 8 B). Activation of CR3 by LPS in the presence of NHP 
was completely blocked by anti-CD14 mAb 3C10 at 10 #g/ml 
(data not shown). Since CR3 also binds constituents on the 
surface of endothelium (20,  21), the activation of this adhe- 
sion molecule may contribute to the neutropenia observed 
in animals exposed to endotoxin. 
The above results indicate that NHP contains an activity 
that enables  a CD14-dependent response of PMN to LPS, 
and the high titer of this activity in plasma suggests that 
it may result from septin rather than LBP. To determine if 
this activity has the characteristics  of septin, we determined 
whether it could be stably deposited on LPS in a fashion that 
requires  proteolytic activity. Tissue culture plastic surfaces 
were first coated with purified LPS and washed. Interaction 
of PMN with these coated surfaces caused no activation of 
CR3 (Fig.  9).  Incubation of the LPS-coated surfaces with 
NHP or LBP, using conditions similar to those required for 
deposition of septin on the surface of ELPS, yielded a surface 
that caused strong activation of CR3  on adherent PMN. 
Generation of surfaces capable of activating PMN was abso- 
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Figure 9.  Plasma opsonizes LPS for recognition by PMN in a Pefabloc- 
sensitive fashion.  Culture surfaces were coated  with 100 ng/ml LPS as 
indicated.  Surfaces were then washed and incubated  for 10 min at 21~ 
with 0.2%  NHP of 0.2 #g/ml LBP diluted  in the presence or absence 
of 15 mM Pefabloc SC. After a further wash, PMN were added, and the 
activation  of CR3 was measured  by the addition of EC3bi as described 
in Materials  and Methods. 
lutely dependent on the presence of both LPS and either plasma 
or LBP (Fig. 9), and the stimulation of PMN was completely 
blocked by mAbs against CD14 (not shown). These results 
suggest that stimulation of PMN by LPS requires deposition 
of serum proteins on LPS and subsequent interaction with 
CD14. Addition of Pefabloc SC during opsonization of the 
LPS surface completely inhibited the opsonization by NHP 
but had no effect on the action of LBP (Fig. 9). Thus, the 
factors in NHP that enable responses of PMN act by binding 
to LPS through a mechanism that requires  proteolytic ac- 
tivity. We thus suggest that stimulation of PMN by LPS re- 
quires  the factors in serum we have termed septin. 
Septin Mediates Stimulation of Monocytes by LPS.  Incuba- 
tion of freshly isolated, platelet-free monocytes with LPS at 
a concentration up to 1 ng/ml LPS induced little TNF secre- 
tion, but addition of serum caused strong TNF synthesis in 
response to 0.01 ng/ml LPS (Fig.  10 A). Serum thus con- 
tributes a factor necessary for responses of monocytes to low 
levels of LPS. 
Several results suggest that septin is the factor in serum 
that enables responses of monocytes to concentrations of LPS 
<1 ng/ml. Induction of TNF by LPS was enabled by dilu- 
tions of serum >3,000-fold (Fig.  10 B), and this response 
was completely blocked by anti-CD14 mAb but not by an 
antibody against HLA (Fig.  10), confirming our previous 
finding with whole blood (8). Adherence of monocytes to 
a plastic surface coated with LPS induced modest TNF secre- 
tion, but opsonization of the surface with dilutions of plasma 
caused a much larger response (Fig.  11). Finally, the ability 
of plasma to opsonize LPS and enable secretion of TNF was 
blocked by the addition of Pefabloc SC during opsonization 
(Fig.  11). These results indicate that induction of TNF syn- 
thesis by MO requires  prior interaction of plasma compo- 
nents with the LPS, and that interaction requires proteolytic 
activity. 
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Figure 10.  Serum is necessary for induction of TNF by low levels of 
LPS. (.4) Platelet-free mononudear cells were incubated for 5 h with the 
indicated concentrations  of LPS in the presence  (')  or absence (O) of 
0.5% NHS, and TNF levels in the medium were measured.  The histo- 
gram depicts responses to 0.1 ng/ml LPS, and 1% NHP in the presence 
of 20 #g/m] W6/32 (anti-HLA) or 3C10 (anti-CD14).  (B) Cells were 
incubated  with dilutions  of human serum  and a fixed dose of LPS (0.1 
ng/ml), and TNF levels in the medium were measured. Error bars repre- 
sent SD calculated from triplicate data points, and in some cases are smalhr 
than the symbol. These studies are representative of at least three separate 
experiments. 
Discussion 
Here we define a novel biological activity present in serum 
and plasma. This activity, septin, opsonizes LPS-coated par- 
ticles for recognition by CD14 on PMN, monocytes, and MO. 
Interaction of LPS/septin complexes with CD14 causes not 
1,0 
0.8 
0.6 
0.4 
0.2 
0.0 
LPS 
NHP 
--  _  +  +  + 
--  +  +  + 
+Pefabloc 
Figure 11.  Plasma opsomzes  LPS for recognition by monocytes  in a 
Pefabloc-sensitive fashion.  Culture surfaces were coated with 20 ng/ml 
LPS as indicated.  Surfaces were then washed  and incubated  for 10 min 
at 21~  with 0.3% NHP diluted in the presence or absence of 15 mM 
Pefabloc SC. After a further wash,  platelet-free mononuclear cells were 
added, and production of TNP was measured after a 5-h incubation.  Error 
bars represent SD calculated from triplicate data points. This study is rep- 
resentative  of more than  six separate experiments. 
725  Wright et al. only binding of the opsonized particle by leukocytes but also 
stimulation of the adhesive activity of PMN and production 
of TNF by monocytes. A similar requirement for serum to 
support responses of cells to LPS has been shown in several 
previous studies. Cohn and Morse (22) reported dramatic en- 
hancement of microbicidal activity of PMN by LPS, but only 
if serum was also present. A requirement for serum was also 
observed for LPS-dependent priming of PMN for an oxida- 
tive burst (11), for LPS-dependent degranulation of PMN (23), 
for LPS-dependent production of cGMP in hepatocytes (24), 
and for LPS-dependent cytotoxicity of endothelial cells (25). 
Our data suggest that serum enables responses to LPS by sup- 
plying an opsonic activity that recognizes LPS and mediates 
interaction with CD14. 
The mechanism by which septin opsonizes LPS involves 
participation of at least two protein species and requires pro- 
teolytic activity. These properties are suggestive of the ac- 
tion of a protease cascade. While it is dear that septin ac- 
tivity  is  not  an  attribute  of either  the  clotting  or  the 
complement cascades,  septin does resemble a protease cas- 
cade described in the hemolymph of arthropods. This cas- 
cade, which is initiated by endotoxin and results in the for- 
mation of a clot, is the basis  of the "Limuhs  amoebocyte 
lysate" assay for endotoxin. The Limuhs cascade is initiated 
by binding of LPS to the zymogen, factor C  (26).  Factor 
C then undergoes an autolytic cleavage that activates proteo- 
lytic activity against an additional zymogen, factor B. Two 
successive  proteolytic  steps  eventuate  in  cleavage  of  a 
fibrinogen-like molecule that makes up the clot. It is reason- 
able to speculate that septin may be evolutionarily rdated to 
the Limulus cascade. 
The biological activities of septin appear similar to those 
of LBP in that both septin and LBP mediate binding of LPS- 
coated particles to MO (6), and both mediate stimulation 
of PMN (7,  10) and monocytes (8).  They differ,  however, 
in their distribution and mechanism of action. Septin activity 
requires at least two distinct protein species as well as pro- 
teolytic activity, while LBP is a single protein that binds LPS 
effectively in the presence of protease inhibitors. LBP is reported 
to be present in low levels in the serum of healthy rabbits 
and is only abundant after induction of the acute phase re- 
sponse.  In contrast,  septin activity is present at very high 
levels in plasma from healthy adults. Because of the prepon- 
derance of septin in normal plasma, we propose that septin 
represents the principal means for opsonization of LPS for 
recognition by CD14 in healthy hosts. 
Septin appears necessary to enable responses to the low con- 
centrations of LPS that occur in the blood during sepsis. With 
the exception of fulminant meningococcemia (27), LPS con- 
centrations >0.1  ng/ml are practically never observed even 
in severely septic patients (28).  While much higher concen- 
trations of LPS (>10 ng/ml) can stimulate TNF production 
in monocytes and can stimulate mild activation of adhesivity 
in PMN, addition of septin is necessary for responses to con- 
centrations of LPS <0.1 ng/ml. We thus believe that septin 
may represent an important, in vivo mechanism for responding 
to LPS. 
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